Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Curr Treat Options Oncol ; 24(3): 184-211, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36701037

RESUMO

OPINION STATEMENT: Although chimeric antigen receptor T cell immunotherapy has been successfully applied in patients with hematological malignancies, several obstacles still need to be overcome, such as high relapse rates and side effects. Overcoming the limitations of CAR-T cell therapy and boosting the efficacy of CAR-T cell therapy are urgent issues that must be addressed. The exploration of small-molecule compounds in combination with CAR-T cell therapies has achieved promising success in pre-clinical and clinical studies in recent years. Protein kinase inhibitors, demethylating drugs, HDAC inhibitors, PI3K inhibitors, immunomodulatory drugs, Akt inhibitors, mTOR inhibitors, and Bcl-2 inhibitors exhibited potential synergy in combination with CAR-T cell therapy. In this review, we will discuss the recent application of these combination therapies for improved outcomes of CAR-T cell therapy.


Assuntos
Neoplasias Hematológicas , Receptores de Antígenos Quiméricos , Humanos , Fosfatidilinositol 3-Quinases , Imunoterapia Adotiva/efeitos adversos , Neoplasias Hematológicas/terapia , Inibidores de Proteínas Quinases , Terapia Baseada em Transplante de Células e Tecidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA